Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Operating Margin (2016 - 2025)

Historic Operating Margin for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to 15.91%.

  • Ani Pharmaceuticals' Operating Margin rose 297400.0% to 15.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.7%, marking a year-over-year increase of 66000.0%. This contributed to the annual value of 0.1% for FY2024, which is 95500.0% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Operating Margin stood at 15.91% for Q3 2025, which was up 297400.0% from 6.57% recorded in Q2 2025.
  • Ani Pharmaceuticals' Operating Margin's 5-year high stood at 27.19% during Q1 2021, with a 5-year trough of 38.94% in Q4 2021.
  • Moreover, its 5-year median value for Operating Margin was 3.74% (2024), whereas its average is 1.32%.
  • In the last 5 years, Ani Pharmaceuticals' Operating Margin surged by 429400bps in 2021 and then plummeted by -569600bps in 2022.
  • Ani Pharmaceuticals' Operating Margin (Quarter) stood at 38.94% in 2021, then surged by 105bps to 1.93% in 2022, then soared by 165bps to 5.11% in 2023, then tumbled by -145bps to 2.3% in 2024, then skyrocketed by 792bps to 15.91% in 2025.
  • Its Operating Margin stands at 15.91% for Q3 2025, versus 6.57% for Q2 2025 and 13.29% for Q1 2025.